Iovance Biotherapeutics Inc (IOVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 110,768 | 196,508 | 163,078 | 158,134 | 132,469 |
| Marketable Securities | 186,906 | 116,935 | 133,902 | 142,669 | 168,714 |
| Receivables | 102,119 | 81,758 | 82,448 | 66,761 | 59,938 |
| Inventories | 55,590 | 58,376 | 51,678 | 51,710 | 49,833 |
| TOTAL | $464,257 | $466,502 | $442,689 | $429,091 | $422,500 |
| Non-Current Assets | |||||
| PPE Net | 131,464 | 131,394 | 131,112 | 126,650 | 122,473 |
| Investments And Advances | 6,431 | 0 | 8,166 | 0 | 0 |
| Intangibles | 263,894 | 269,104 | 279,324 | 285,208 | 296,253 |
| Other Non-Current Assets | 49,485 | 58,665 | 51,879 | 63,999 | 66,211 |
| TOTAL | $451,274 | $459,163 | $470,481 | $475,857 | $484,937 |
| Total Assets | $915,531 | $925,665 | $913,170 | $904,948 | $907,437 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 26,211 | 37,450 | 22,159 | 31,237 | 32,004 |
| Accrued Expenses | 77,964 | 88,071 | 111,156 | 87,267 | 89,081 |
| TOTAL | $106,848 | $129,420 | $138,358 | $125,785 | $129,155 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 43,330 | 43,877 | 44,401 | 45,211 | 45,096 |
| TOTAL | $72,638 | $74,491 | $76,229 | $76,876 | $79,794 |
| Total Liabilities | $179,486 | $203,911 | $214,587 | $202,661 | $208,949 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 452,971 | 446,502 | 411,962 | 396,968 | 361,854 |
| Common Shares | 19 | 18 | 17 | 16 | 14 |
| Retained earnings | -2,901,890 | -2,854,575 | -2,775,530 | -2,703,626 | -2,612,373 |
| Other shareholders' equity | 13,078 | 12,650 | 16,440 | 16,103 | 20,859 |
| TOTAL | $736,045 | $721,754 | $698,583 | $702,287 | $698,488 |
| Total Liabilities And Equity | $915,531 | $925,665 | $913,170 | $904,948 | $907,437 |